02/05/2026
Πριν καν κυκλοφορήσει στην Ευρώπη το σκεύασμα απευαισθητοποίησης για την αλλεργία στο φιστίκι, διακόπηκε και η παραγωγή του στις ΗΠΑ. Δυστυχώς μια παραγωγή φαρμακευτικού σκευάσματος είναι και θέμα εμπορικού κέρδους αλλά και άλλων παραγόντων.
Τουλάχιστον υπάρχει η αδρεναλίνη για την αντιμετώπιση της αναφυλαξίας, η εκπαίδευση του ασθενούς αλλά και άλλα θεραπευτικά μέσα που προσφέρει η αλλεργιολογία.
The discontinuation of Palforzia marks a complicated moment for the food allergy community.
“Palforzia was the first FDA approved therapeutic to treat any food allergy, marking a shift from avoidance as the only option for kids with a peanut allergy. It was a watershed moment,” Sung Poblete said to Healio.
That’s why this news is so difficult. “Palforzia is one of only two FDA-approved therapeutics for food allergy, so it’s really disappointing to see all the R&D that was put into its development be lost, not to mention the brave patients who participated in the clinical trials to get the drug to approval,” Poblete added.
At the same time, progress is not stopping.
There are still centers offering oral immunotherapy, along with emerging approaches like sublingual and epicutaneous immunotherapy that could expand options in the near future. Research is actively underway, including a FARE-funded study exploring how to safely treat multiple allergens at once.
And this is exactly where continued investment and collaboration matter most. Through initiatives like the Mind Meld Innovation Summit, FARE is bringing together researchers, clinicians, industry, and federal partners to accelerate the next generation of breakthroughs.
Progress in food allergy has never been linear. But even in moments like this, the path forward is clear: more innovation, more access, and a continued commitment to changing what life with food allergy looks like. Read more here: https://www.healio.com/news/allergy-asthma/20260428/qa-palforzias-discontinuation-disappointing-but-new-options-may-be-forthcoming
